Evidence that the IGFBP-5 protein contributes to the development of pulmonary fibrosis was supported by new research finding that its higher-than-normal levels in people with fibrotic disease help to drive other pro-fibrotic proteins and factors.
The study, “IGFBP-5 Promotes Fibrosis via Increasing Its Own Expression and That of Other Pro-fibrotic Mediators,” adds to a growing body of literature suggesting that IGFBP-5 is an important player in mediating fibrosis. It was published in Frontiers in Endocrinology.
Pulmonary fibrosis is a major complication of several diseases, including systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF), and has limited therapeutic options.
Studies have shown that expression of IGFBP-5 — meaning the activity of the gene responsible for producing this protein — is increased in the skin and lung tissues of patients with SSc and IPF. Additionally, it was shown in multiple models that IGFBP-5 increases the production of proteins in the extracellular matrix — the space around cells. The extracellular matrix provides a surface for adhesion and a space for other signaling components.
IGFBPs (insulin-like growth factor-binding proteins) are made up of six different proteins that are secreted from the cell into the extracellular matrix.
Researchers wanted to better understand if IGFBP-5 could contribute to fibrosis development by regulating the expression of known pro-fibrotic factors, such as CTGF and LOX.
By adding recombinant IGFBP-5 to human primary lung fibroblasts from healthy donors, they found that IGFBP-5 increases the expression of both CTGF and LOX.
The researchers also confirmed that IGFBP-5 increased the levels of extracellular matrix-related proteins, namely collagen 1A1 and fibronectin, thereby promoting fibrosis.
And they showed that IGFBP-5 could stimulate its own expression, creating a positive-feedback loop that can perpetually promote fibrosis.
Of note, these changes in gene expression were seen early after addition of IGFBP-5 to lung cells, suggesting that they are early response genes and are important in promoting later, downstream events.
Increased levels of the pro-fibrotic proteins CTGF and LOX were also seen when the research team used a viral-based gene therapy to increase the expression of IGFPB-5.
Another way to assess the function of a gene is by decreasing its activity. For this purpose, the team used small-interfering RNA technology to lower the expression of IGFBP-5 in lung fibroblasts from healthy donors or patients with IPF or SSc.
Decreasing IGFBP-5 levels had different effects in healthy donors and SSc or IPF patients. Decreasing IGFBP-5 in cells from IPF patients also lowered the expression of the pro-fibrotic factor CTGF, but no significant difference in CTGF levels after silencing IGFBP-5 expression was seen in those from healthy donors. There was a trend toward decreased CTGF levels in lung cells from patients with SSc, but it do not reach statistical significance.
“Together, our data extend our previous findings and demonstrate that IGFBP-5 exerts its pro-fibrotic activity by directly inducing expression of ECM [extracellular matrix] and pro-fibrotic genes,” the researchers wrote.
The team believes that IGFBP-5 is a major player in the development of pulmonary fibrosis, and that it “likely acts in concert with other growth factors to drive fibrosis and tissue remodeling.” Therefore, “strategies to inhibit IGFBP-5 function might be effective for the amelioration of fibrosis,” the team concluded.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?